Cargando…

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy

The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIR...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin, Jin, Shenhe, Guo, Xiaojun, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259379/
https://www.ncbi.nlm.nih.gov/pubmed/30226089
http://dx.doi.org/10.1177/0300060518799612
_version_ 1783374665008283648
author Zhang, Jin
Jin, Shenhe
Guo, Xiaojun
Qian, Wenbin
author_facet Zhang, Jin
Jin, Shenhe
Guo, Xiaojun
Qian, Wenbin
author_sort Zhang, Jin
collection PubMed
description The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma.
format Online
Article
Text
id pubmed-6259379
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-62593792018-11-30 Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy Zhang, Jin Jin, Shenhe Guo, Xiaojun Qian, Wenbin J Int Med Res Reviews The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma. SAGE Publications 2018-09-18 2018-11 /pmc/articles/PMC6259379/ /pubmed/30226089 http://dx.doi.org/10.1177/0300060518799612 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Reviews
Zhang, Jin
Jin, Shenhe
Guo, Xiaojun
Qian, Wenbin
Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
title Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
title_full Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
title_fullStr Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
title_full_unstemmed Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
title_short Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
title_sort targeting the cd47-sirpα signaling axis: current studies on b-cell lymphoma immunotherapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259379/
https://www.ncbi.nlm.nih.gov/pubmed/30226089
http://dx.doi.org/10.1177/0300060518799612
work_keys_str_mv AT zhangjin targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy
AT jinshenhe targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy
AT guoxiaojun targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy
AT qianwenbin targetingthecd47sirpasignalingaxiscurrentstudiesonbcelllymphomaimmunotherapy